Clinical Trial Update: A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety and immunogenicity of the HIV-1 DNA vaccine APL-400-047 delivered by needle-syringe or Biojector in HIV-uninfected adults; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APL-400-047

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED